Ann: Investor Presentation, page-30

No worries, @Owl vs Fox.

I prefer to read the research firstly to see the basis of which Imugene have created their developmental drugs on. I may not understand it entirely but it gives some further insights about how at least it works pre-clinically.

I'm in the webinar at the moment and I believe one of the researchers has mentioned that, as far as their knowledge goes, no one else is working in this space. I recall he was responding to a question about whether other companies are doing something similar as the OnCARlytics combination. They truly have a solid scientific team.

If anyone wants the full research article by Park et al. (2020), please let me know.